Company intelligence / Profile preview
Link Cell Therapies
San Carlos, California, United Stateslinkcelltx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Link Cell Therapies has demonstrated in preclinical models that its LINK CARs can specifically activate T cells to eradicate tumors in vivo while sparing normal tissues. The company’s foundational work was published in Nature in 2023, showing the potential for their logic-gate technology to address solid tumors without off-tumor toxicity. No human clinical results have been reported yet[10].
- Therapeutic areas
- Oncology
- Modalities
- CAR T cell therapiesgene-edited cell therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Samsara BioCapital and Sheatree Capital as founding investors/partners; no major pharma partnerships announced yet
Beyond the preview
Go deeper on Link Cell Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Link Cell Therapies.